Understanding how the immune system affects the progression of oral pre-cancer to cancer
Immune determinants of progression from Oral Epithelial Dysplasia to Oral Squamous Cell Carcinoma by precision multiplexed imaging
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11060001
This study is looking at how the immune system affects whether a condition called oral epithelial dysplasia turns into oral cancer, so that patients with this condition can get better monitoring and personalized treatments based on their immune responses.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11060001 on ClinicalTrials.gov |
What this research studies
This research investigates the immune factors that influence whether oral epithelial dysplasia (OED) progresses to oral squamous cell carcinoma (OSCC). By using advanced imaging techniques, the study aims to identify specific immune responses that could indicate a higher risk of cancer development. Patients with OED may be monitored more closely and receive tailored treatments based on their immune profiles. The goal is to improve early detection and intervention strategies for those at risk of developing invasive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with oral epithelial dysplasia who are at risk of progressing to oral squamous cell carcinoma.
Not a fit: Patients with established oral squamous cell carcinoma or those without any signs of oral epithelial dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective early treatments for patients with pre-cancerous lesions, potentially reducing the progression to cancer.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in cancer progression, suggesting that this approach could yield valuable insights.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPITZER, MATTHEW — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SPITZER, MATTHEW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.